Tuesday, May 19, 2020
Moderna Inc's experimental COVID-19 vaccine, the first to be tested in the United States, produced protective antibodies in a small group of healthy volunteers, according to very early data released by the biotech company on 18th May 2020.
Overall, the study showed the vaccine was safe and all study participants produced antibodies against the virus.
The news, issued in a release by the U.S. biotechnology company, lifted shares of Moderna by 20%.
Moderna launched a $1.34 billion share offering at an offer price of $76 per share late Monday. The company had earlier said it plans to sell $1.25 billion in common stock to raise money for vaccine development and manufacturing.
